A Phase IV, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of VI-0521 on the Glomerular Filtration Rate of Healthy Overweight or Obese Subjects

Trial Profile

A Phase IV, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of VI-0521 on the Glomerular Filtration Rate of Healthy Overweight or Obese Subjects

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2016

At a glance

  • Drugs Phentermine/topiramate (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Sponsors VIVUS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Sep 2014 Planned End Date changed from 1 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top